View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAbcam 将来の成長Future 基準チェック /46主要情報32.8%収益成長率39.10%EPS成長率Biotechs 収益成長22.8%収益成長率13.4%将来の株主資本利益率n/aアナリストカバレッジGood最終更新日n/a今後の成長に関する最新情報お知らせ • Sep 13Abcam plc Provides Revenue Guidance for the Full Year Ending December 31, 2022Abcam plc provided revenue guidance for the full year ending December 31, 2022. For the year, the company currently estimate total revenue to increase approximately 20% CER including the impact from the acquisition of BioVision, with organic CER growth of mid-teens. The company expects the contribution from the sale of higher margin in-house products and the full year effect of BioVision to contribute to a continuing increase in adjusted operating margins.お知らせ • Jan 28Abcam plc Provides Group Revenue Guidance for the Twelve Months Ended 31 December 2021Abcam plc provided group revenue guidance for the twelve months ended 31 December 2021. For the year, the company Group expects to report total revenues of approximately £315 million, representing growth of over 22% on a constant exchange rate basis and 17% on a reported basis (12 months to 31 December 2020: £269.3 million). This figure includes a contribution of approximately £2.5 million of incremental revenue1 from BioVision following the acquisition's completion on 27 October 2021.お知らせ • Sep 15Abcam plc Provides Revenue Guidance for the Six-Months to 31 December 2021 and Year Ending December 31, 2024Abcam plc provided revenue guidance for the six-months to 31 December 2021 and year ending December 31, 2024. For the six months to December 31, 2021, the company expects revenue growth to be approximately 6%. For the year ending December 31, 2024, the company expects revenue to be £425 – 500 million.すべての更新を表示Recent updatesお知らせ • Dec 13Abcam Provides Update on AIM DelistingAbcam plc provided a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM (the "AIM Delisting"), as originally announced on 17 October 2022. As previously announced, the last day of trading of the Company's Ordinary Shares on AIM will be 13 December 2022 and the proposed AIM Delisting will be effective from 7.00 a.m. (London time) on 14 December 2022. Abcam will retain the listing of its ADSs, each representing one Ordinary Share, on Nasdaq under the ticker symbol ABCM. Following the AIM Delisting, the Company's ADSs will remain listed, and will only be tradeable, on Nasdaq.お知らせ • Oct 18Abcam plc Announces Proposed Cancellation of AIM SharesAbcam plc announced the Company's intention to cancel the admission of its ordinary shares of nominal value 0.02 pence each (the "Ordinary Shares") to trading on AIM (the "AIM Delisting"), subject to shareholder approval, with effect from December 14, 2022. Subject to shareholder approval, the Company's last day of trading on AIM will be December 13, 2022. Abcam will retain the listing on the Nasdaq Global Select Market ("Nasdaq") of American Depositary Shares, each representing one Ordinary Share (the "ADSs"), under ticker symbol "ABCM", and all public trading of securities in the Company will take place on that exchange. Existing holders of ADSs not also holding Ordinary Shares do not need to take any action in relation to the AIM Delisting; and the posting of a circular to Abcam shareholders (the "Circular"), which contains further information on the AIM Delisting and the process to deposit Ordinary Shares for delivery of ADSs and notice of a general meeting to be held on 11 November 2022 at Discovery Drive, Cambridge Biomedical Campus, Cambridge, CB2 0AX, United Kingdom at 2.00 p.m. (London time) (the "General Meeting") at which shareholder approval will be sought, inter alia, for the AIM Delisting.お知らせ • Sep 13Abcam plc Provides Revenue Guidance for the Full Year Ending December 31, 2022Abcam plc provided revenue guidance for the full year ending December 31, 2022. For the year, the company currently estimate total revenue to increase approximately 20% CER including the impact from the acquisition of BioVision, with organic CER growth of mid-teens. The company expects the contribution from the sale of higher margin in-house products and the full year effect of BioVision to contribute to a continuing increase in adjusted operating margins.お知らせ • Sep 12Abcam plc Appoints Luba Greenwood as Non-Executive DirectorAbcam plc announced the appointment of Luba Greenwood as a non-executive Director with immediate effect. Luba's experiences focus on business development and strategy. She is a veteran biotech, pharmaceutical, tech, and life sciences investor and company builder. Luba has held a number of senior leadership and board positions in the healthcare industry. Currently, she serves as the managing partner of the Dana Farber Cancer Institute Venture Fund, Binney Street Capital (BSC), which she has built and launched. Luba is also the CEO of Kojin Therapeutics. Her previous experience includes increasing levels of responsibility at Google Life Sciences, Verily and F. Hoffman-La Roche. Luba has extensive board experience, and currently serves on the board of directors of the following private institutions: MassBio, BenchSci, and In8Bio Inc. Following Luba's appointment, the composition of each of the Board Committees is confirmed as follows: Nomination Committee: Peter Allen (Chair), Mara Aspinall, Giles Kerr. Remuneration Committee: Sally W. Crawford (Chair), Mara Aspinall, Peter Allen, Giles Kerr, Mark Capone. Audit and Risk Committee: Giles Kerr (Chair), Mara Aspinall, Sally W. Crawford.お知らせ • Jul 21+ 1 more updateAbcam Board Decides to Pursue A Proposal to Cancel the Admission of the Shares to Trading on AimHaving consulted with shareholders on options to increase share liquidity as announced on March 14, 2022, the Board of Abcam plc has decided to pursue a proposal to maintain a sole listing on Nasdaq and therefore to cancel the admission of the Company's shares to trading on AIM. The Company will continue to consult with shareholders on this proposal in the coming weeks with the intention to put the proposal to shareholder approval at a General Meeting called for that purpose later this year.お知らせ • Jun 23Abcam plc to Report First Half, 2022 Results on Sep 12, 2022Abcam plc announced that they will report first half, 2022 results on Sep 12, 2022Recent Insider Transactions • Apr 09Key Executive recently bought €80k worth of stockOn the 4th of April, Peter Allen bought around 5k shares on-market at roughly €17.14 per share. This was the largest purchase by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months.お知らせ • Apr 05Abcam plc, Annual General Meeting, May 18, 2022Abcam plc, Annual General Meeting, May 18, 2022, at 12:00 Coordinated Universal Time. Location: Discovery Drive, Cambridge Biomedical Campus Cambridge CB2 0AX Cambridge United Kingdom Agenda: To receive and adopt the reports of the directors and the financial statements for the period ended 31 December 2021, together with the Independent Auditor's Report; to approve the Annual Report on Directors' Remuneration for the period ended 31 December 2021, as set out on pages 93 to 103 of the Annual Report and Accounts; to approve the Remuneration Policy, as set out on pages 104 to 117 of the Annual Report and Accounts; to re-appoint PricewaterhouseCoopers LLP as auditor of the Company to hold office until the conclusion of the next general meeting at which accounts are laid before the Company; to authorise the Audit and Risk Committee to fix the remuneration of the auditor; to re-elect Directors.Reported Earnings • Mar 15Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: UK£0.019 (up from UK£0.009 loss in FY 2020). Revenue: UK£315.4m (up 17% from FY 2020). Net income: UK£4.40m (up UK£6.30m from FY 2020). Profit margin: 1.4% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 19%, compared to a 76% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.お知らせ • Feb 28Abcam plc to Report 18 Months Period Ending Dec 31, 2021 Results on Mar 14, 2022Abcam plc announced that they will report 18 months, period ending Dec 31, 2021 results at 8:00 AM, US Eastern Standard Time on Mar 14, 2022お知らせ • Jan 28Abcam plc Provides Group Revenue Guidance for the Twelve Months Ended 31 December 2021Abcam plc provided group revenue guidance for the twelve months ended 31 December 2021. For the year, the company Group expects to report total revenues of approximately £315 million, representing growth of over 22% on a constant exchange rate basis and 17% on a reported basis (12 months to 31 December 2020: £269.3 million). This figure includes a contribution of approximately £2.5 million of incremental revenue1 from BioVision following the acquisition's completion on 27 October 2021.Recent Insider Transactions • Sep 26CEO & Executive Director recently sold €110k worth of stockOn the 23rd of September, Alan Hirzel sold around 6k shares on-market at roughly €17.98 per share. This was the largest sale by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months.Reported Earnings • Sep 15Full year 2021 earnings released: EPS UK£0.073 (vs UK£0.06 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£297.7m (up 14% from FY 2020). Net income: UK£16.2m (up 30% from FY 2020). Profit margin: 5.4% (up from 4.8% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.お知らせ • Sep 15Abcam plc Provides Revenue Guidance for the Six-Months to 31 December 2021 and Year Ending December 31, 2024Abcam plc provided revenue guidance for the six-months to 31 December 2021 and year ending December 31, 2024. For the six months to December 31, 2021, the company expects revenue growth to be approximately 6%. For the year ending December 31, 2024, the company expects revenue to be £425 – 500 million.お知らせ • Aug 04Abcam plc (AIM:ABC) entered into a definitive agreement to acquire BioVision, Inc. from Boai NKY Medical Holdings Ltd. (SZSE:300109) for approximately $340 million.Abcam plc (AIM:ABC) entered into a definitive agreement to acquire BioVision, Inc. from Boai NKY Medical Holdings Ltd. (SZSE:300109) for approximately $340 million on August 2, 2021. The consideration of $340 million will be paid on a cash free/debt free basis. Acquisition to be funded from existing cash resources and a partial drawdown of Abcam's Revolving Credit Facility. Acquisition agreement provides for the payment of a reciprocal termination fee of approximately 3% of the purchase price, in the event the Acquisition is terminated in certain specified circumstances. As of December 30, 2020, BioVision generated revenues of $33.8 million, operating profit of $12.6 million, and had Net assets of $21.9 million. The acquisition is expected to be accretive to adjusted earnings per share (EPS) from the first full year of ownership. The acquisition is subject to applicable regulatory clearance and will be subject to review and approval of the Shenzhen Stock Exchange and by a vote of NKY's shareholders. If approved, the acquisition is expected to close before the end of 2021 calendar year. Lazard is acting as financial adviser and Latham & Watkins LLP is acting as legal advisor to Abcam in relation to this transaction. Garry Levin, Freddie Barnfield, and Duncan Monteith of Numis acted as nominated advisors and joint corporate brokers to Abcam.Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardMara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardMara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardMara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardMara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardMara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardMara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Executive Departure • May 27Senior Independent Director has left the companyOn the 19th of May, Louise A. V. Patten's tenure as Senior Independent Director ended after 6.5 years in the role. As of March 2021, Louise A. V. personally held 54.84k shares (€891k worth at the time). Louise A. V. is the only executive to leave the company over the last 12 months.Reported Earnings • Mar 10First half 2021 earnings released: EPS UK£0.053 (vs UK£0.13 in 1H 2020)The company reported a soft first half result with weaker earnings and profit margins, although revenues improved. First half 2021 results: Revenue: UK£147.5m (up 6.7% from 1H 2020). Net income: UK£11.7m (down 55% from 1H 2020). Profit margin: 7.9% (down from 19% in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Mar 09Revenue beats expectationsRevenue exceeded analyst estimates by 1.3%. Over the next year, revenue is forecast to grow 18%, compared to a 57% growth forecast for the Biotechs industry in Germany.Is New 90 Day High Low • Feb 13New 90-day high: €19.25The company is up 25% from its price of €15.36 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.75 per share.お知らせ • Feb 10Abingdon Health Signs Collaboration and Co-Marketing Agreement with AbcamAbingdon Health Plc has signed a collaboration and co-marketing agreement with Abcam plc. The Parties intend to establish a collaborative strategic relationship to enable them to identify and maximise opportunities for the provision of each Party’s respective products and services, including the wider Abcam reagent portfolio and Abingdon Health’s rapid test contract development and manufacturing services. Under the terms of the agreement, Abcam will be the preferred supplier to Abingdon of gold nanoparticles and custom conjugation reagents and services, for the Company’s lateral flow assays. Custom conjugation reagents will include a combination of an affinity binding reagent such as an antibody, and signal reagents such as the colloidal gold which provides the colour output in a lateral flow assay. Securing a reliable source for custom conjugation reagents ensures reliable supply chains of critical reagents for customers of Abingdon by providing access to the reagents, colloidal gold and specialist conjugation services of Abcam.お知らせ • Jan 29Abcam plc Appoints Non-Executive DirectorsAbcam plc announced the appointments of Bessie Lee and Mark Capone as non-executive Directors with immediate effect. Based in China, Bessie Lee is the Chief Executive Officer of Withinlink. Based in the US, Mark Capone is an accomplished life sciences executive with more than 35 years’ experience. He spent over 17 years with Myriad Genetics, latterly as Chief Executive Officer and President, over which time he grew the company into a leading global precision medicine company.Is New 90 Day High Low • Jan 13New 90-day high: €17.98The company is up 29% from its price of €13.91 on 15 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.22 per share.お知らせ • Dec 23Abcam plc to Report Q2, 2021 Results on Mar 08, 2021Abcam plc announced that they will report Q2, 2021 results on Mar 08, 2021お知らせ • Nov 04Abcam plc, Annual General Meeting, Dec 04, 2020Abcam plc, Annual General Meeting, Dec 04, 2020, at 12:00 Coordinated Universal Time. Location: Discovery Drive, Cambridge Biomedical Campus Cambridge United Kingdom Agenda: To consider and adopt the reports of the directors and the financial statements for the year ended 30 June 2020, together with the independent auditor’s report; to consider and approve the Annual report on directors’ remuneration for the year ended 30 June 2020, as set out on pages 84 to 93 of the annual report and accounts.; to consider re-appoint PricewaterhouseCoopers LLP as auditor of the company to hold office until the conclusion of the next general meeting at which accounts are laid before the company; to consider and authorise the Audit and Risk Committee to fix the remuneration of the auditor; and to consider election of director.Is New 90 Day High Low • Oct 22New 90-day high: €15.13The company is up 5.0% from its price of €14.42 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.69 per share.Reported Earnings • Oct 04Full year earnings released - EPS €0.06Over the last 12 months the company has reported total profits of UK£12.5m, down 72% from the prior year. Total revenue was UK£260.0m over the last 12 months, largely unchanged from the prior year. Profit margins were 4.8%, which is lower than the 17% margin from last year. The decrease in margin was driven by higher expenses.Recent Insider Transactions • Sep 25Non-Executive Chairman recently bought €49k worth of stockOn the 17th of September, Peter Allen bought around 4k shares on-market at roughly €13.73 per share. This was the largest purchase by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months.お知らせ • Jul 20Abcam plc to Report Fiscal Year 2020 Results on Sep 14, 2020Abcam plc announced that they will report fiscal year 2020 results on Sep 14, 2020業績と収益の成長予測DB:A8C1 - アナリストの将来予測と過去の財務データ ( )GBP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025567105N/A211312/31/202449978135155712/31/20234486188133912/31/202238838499296/30/202235071255N/A3/31/20223336759N/A12/31/20213154363N/A6/30/2021298161572N/A3/31/202128471465N/A12/31/2020295261867N/A9/30/202026552060N/A6/30/2020260132763N/A3/31/2020267273167N/A12/31/2019273433673N/A9/30/2019267443372N/A6/30/2019260443069N/A3/31/2019253512569N/A12/31/2018245582167N/A9/30/2018239602365N/A6/30/2018233622663N/A3/31/2018230593564N/A12/31/2017227554464N/A9/30/2017222494665N/A6/30/2017217424766N/A3/31/2017206414564N/A12/31/2016196404362N/A9/30/2016184393755N/A6/30/2016172373247N/A3/31/201616437N/A45N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A8C1の予測収益成長率 (年間32.8% ) は 貯蓄率 ( 0.03% ) を上回っています。収益対市場: A8C1の収益 ( 32.8% ) はGerman市場 ( 17.1% ) よりも速いペースで成長すると予測されています。高成長収益: A8C1の収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: A8C1の収益 ( 13.4% ) German市場 ( 6.7% ) よりも速いペースで成長すると予測されています。高い収益成長: A8C1の収益 ( 13.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A8C1の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/01/18 10:10終値2022/12/13 00:00収益2022/06/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Abcam plc 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Xian DengBerenbergMichael RyskinBofA Global ResearchPaul KnightBrean Capital Historical (Janney Montgomery)15 その他のアナリストを表示
お知らせ • Sep 13Abcam plc Provides Revenue Guidance for the Full Year Ending December 31, 2022Abcam plc provided revenue guidance for the full year ending December 31, 2022. For the year, the company currently estimate total revenue to increase approximately 20% CER including the impact from the acquisition of BioVision, with organic CER growth of mid-teens. The company expects the contribution from the sale of higher margin in-house products and the full year effect of BioVision to contribute to a continuing increase in adjusted operating margins.
お知らせ • Jan 28Abcam plc Provides Group Revenue Guidance for the Twelve Months Ended 31 December 2021Abcam plc provided group revenue guidance for the twelve months ended 31 December 2021. For the year, the company Group expects to report total revenues of approximately £315 million, representing growth of over 22% on a constant exchange rate basis and 17% on a reported basis (12 months to 31 December 2020: £269.3 million). This figure includes a contribution of approximately £2.5 million of incremental revenue1 from BioVision following the acquisition's completion on 27 October 2021.
お知らせ • Sep 15Abcam plc Provides Revenue Guidance for the Six-Months to 31 December 2021 and Year Ending December 31, 2024Abcam plc provided revenue guidance for the six-months to 31 December 2021 and year ending December 31, 2024. For the six months to December 31, 2021, the company expects revenue growth to be approximately 6%. For the year ending December 31, 2024, the company expects revenue to be £425 – 500 million.
お知らせ • Dec 13Abcam Provides Update on AIM DelistingAbcam plc provided a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM (the "AIM Delisting"), as originally announced on 17 October 2022. As previously announced, the last day of trading of the Company's Ordinary Shares on AIM will be 13 December 2022 and the proposed AIM Delisting will be effective from 7.00 a.m. (London time) on 14 December 2022. Abcam will retain the listing of its ADSs, each representing one Ordinary Share, on Nasdaq under the ticker symbol ABCM. Following the AIM Delisting, the Company's ADSs will remain listed, and will only be tradeable, on Nasdaq.
お知らせ • Oct 18Abcam plc Announces Proposed Cancellation of AIM SharesAbcam plc announced the Company's intention to cancel the admission of its ordinary shares of nominal value 0.02 pence each (the "Ordinary Shares") to trading on AIM (the "AIM Delisting"), subject to shareholder approval, with effect from December 14, 2022. Subject to shareholder approval, the Company's last day of trading on AIM will be December 13, 2022. Abcam will retain the listing on the Nasdaq Global Select Market ("Nasdaq") of American Depositary Shares, each representing one Ordinary Share (the "ADSs"), under ticker symbol "ABCM", and all public trading of securities in the Company will take place on that exchange. Existing holders of ADSs not also holding Ordinary Shares do not need to take any action in relation to the AIM Delisting; and the posting of a circular to Abcam shareholders (the "Circular"), which contains further information on the AIM Delisting and the process to deposit Ordinary Shares for delivery of ADSs and notice of a general meeting to be held on 11 November 2022 at Discovery Drive, Cambridge Biomedical Campus, Cambridge, CB2 0AX, United Kingdom at 2.00 p.m. (London time) (the "General Meeting") at which shareholder approval will be sought, inter alia, for the AIM Delisting.
お知らせ • Sep 13Abcam plc Provides Revenue Guidance for the Full Year Ending December 31, 2022Abcam plc provided revenue guidance for the full year ending December 31, 2022. For the year, the company currently estimate total revenue to increase approximately 20% CER including the impact from the acquisition of BioVision, with organic CER growth of mid-teens. The company expects the contribution from the sale of higher margin in-house products and the full year effect of BioVision to contribute to a continuing increase in adjusted operating margins.
お知らせ • Sep 12Abcam plc Appoints Luba Greenwood as Non-Executive DirectorAbcam plc announced the appointment of Luba Greenwood as a non-executive Director with immediate effect. Luba's experiences focus on business development and strategy. She is a veteran biotech, pharmaceutical, tech, and life sciences investor and company builder. Luba has held a number of senior leadership and board positions in the healthcare industry. Currently, she serves as the managing partner of the Dana Farber Cancer Institute Venture Fund, Binney Street Capital (BSC), which she has built and launched. Luba is also the CEO of Kojin Therapeutics. Her previous experience includes increasing levels of responsibility at Google Life Sciences, Verily and F. Hoffman-La Roche. Luba has extensive board experience, and currently serves on the board of directors of the following private institutions: MassBio, BenchSci, and In8Bio Inc. Following Luba's appointment, the composition of each of the Board Committees is confirmed as follows: Nomination Committee: Peter Allen (Chair), Mara Aspinall, Giles Kerr. Remuneration Committee: Sally W. Crawford (Chair), Mara Aspinall, Peter Allen, Giles Kerr, Mark Capone. Audit and Risk Committee: Giles Kerr (Chair), Mara Aspinall, Sally W. Crawford.
お知らせ • Jul 21+ 1 more updateAbcam Board Decides to Pursue A Proposal to Cancel the Admission of the Shares to Trading on AimHaving consulted with shareholders on options to increase share liquidity as announced on March 14, 2022, the Board of Abcam plc has decided to pursue a proposal to maintain a sole listing on Nasdaq and therefore to cancel the admission of the Company's shares to trading on AIM. The Company will continue to consult with shareholders on this proposal in the coming weeks with the intention to put the proposal to shareholder approval at a General Meeting called for that purpose later this year.
お知らせ • Jun 23Abcam plc to Report First Half, 2022 Results on Sep 12, 2022Abcam plc announced that they will report first half, 2022 results on Sep 12, 2022
Recent Insider Transactions • Apr 09Key Executive recently bought €80k worth of stockOn the 4th of April, Peter Allen bought around 5k shares on-market at roughly €17.14 per share. This was the largest purchase by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months.
お知らせ • Apr 05Abcam plc, Annual General Meeting, May 18, 2022Abcam plc, Annual General Meeting, May 18, 2022, at 12:00 Coordinated Universal Time. Location: Discovery Drive, Cambridge Biomedical Campus Cambridge CB2 0AX Cambridge United Kingdom Agenda: To receive and adopt the reports of the directors and the financial statements for the period ended 31 December 2021, together with the Independent Auditor's Report; to approve the Annual Report on Directors' Remuneration for the period ended 31 December 2021, as set out on pages 93 to 103 of the Annual Report and Accounts; to approve the Remuneration Policy, as set out on pages 104 to 117 of the Annual Report and Accounts; to re-appoint PricewaterhouseCoopers LLP as auditor of the Company to hold office until the conclusion of the next general meeting at which accounts are laid before the Company; to authorise the Audit and Risk Committee to fix the remuneration of the auditor; to re-elect Directors.
Reported Earnings • Mar 15Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: UK£0.019 (up from UK£0.009 loss in FY 2020). Revenue: UK£315.4m (up 17% from FY 2020). Net income: UK£4.40m (up UK£6.30m from FY 2020). Profit margin: 1.4% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 19%, compared to a 76% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 28Abcam plc to Report 18 Months Period Ending Dec 31, 2021 Results on Mar 14, 2022Abcam plc announced that they will report 18 months, period ending Dec 31, 2021 results at 8:00 AM, US Eastern Standard Time on Mar 14, 2022
お知らせ • Jan 28Abcam plc Provides Group Revenue Guidance for the Twelve Months Ended 31 December 2021Abcam plc provided group revenue guidance for the twelve months ended 31 December 2021. For the year, the company Group expects to report total revenues of approximately £315 million, representing growth of over 22% on a constant exchange rate basis and 17% on a reported basis (12 months to 31 December 2020: £269.3 million). This figure includes a contribution of approximately £2.5 million of incremental revenue1 from BioVision following the acquisition's completion on 27 October 2021.
Recent Insider Transactions • Sep 26CEO & Executive Director recently sold €110k worth of stockOn the 23rd of September, Alan Hirzel sold around 6k shares on-market at roughly €17.98 per share. This was the largest sale by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months.
Reported Earnings • Sep 15Full year 2021 earnings released: EPS UK£0.073 (vs UK£0.06 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£297.7m (up 14% from FY 2020). Net income: UK£16.2m (up 30% from FY 2020). Profit margin: 5.4% (up from 4.8% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.
お知らせ • Sep 15Abcam plc Provides Revenue Guidance for the Six-Months to 31 December 2021 and Year Ending December 31, 2024Abcam plc provided revenue guidance for the six-months to 31 December 2021 and year ending December 31, 2024. For the six months to December 31, 2021, the company expects revenue growth to be approximately 6%. For the year ending December 31, 2024, the company expects revenue to be £425 – 500 million.
お知らせ • Aug 04Abcam plc (AIM:ABC) entered into a definitive agreement to acquire BioVision, Inc. from Boai NKY Medical Holdings Ltd. (SZSE:300109) for approximately $340 million.Abcam plc (AIM:ABC) entered into a definitive agreement to acquire BioVision, Inc. from Boai NKY Medical Holdings Ltd. (SZSE:300109) for approximately $340 million on August 2, 2021. The consideration of $340 million will be paid on a cash free/debt free basis. Acquisition to be funded from existing cash resources and a partial drawdown of Abcam's Revolving Credit Facility. Acquisition agreement provides for the payment of a reciprocal termination fee of approximately 3% of the purchase price, in the event the Acquisition is terminated in certain specified circumstances. As of December 30, 2020, BioVision generated revenues of $33.8 million, operating profit of $12.6 million, and had Net assets of $21.9 million. The acquisition is expected to be accretive to adjusted earnings per share (EPS) from the first full year of ownership. The acquisition is subject to applicable regulatory clearance and will be subject to review and approval of the Shenzhen Stock Exchange and by a vote of NKY's shareholders. If approved, the acquisition is expected to close before the end of 2021 calendar year. Lazard is acting as financial adviser and Latham & Watkins LLP is acting as legal advisor to Abcam in relation to this transaction. Garry Levin, Freddie Barnfield, and Duncan Monteith of Numis acted as nominated advisors and joint corporate brokers to Abcam.
Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardMara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardMara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardMara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardMara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardMara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardMara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Executive Departure • May 27Senior Independent Director has left the companyOn the 19th of May, Louise A. V. Patten's tenure as Senior Independent Director ended after 6.5 years in the role. As of March 2021, Louise A. V. personally held 54.84k shares (€891k worth at the time). Louise A. V. is the only executive to leave the company over the last 12 months.
Reported Earnings • Mar 10First half 2021 earnings released: EPS UK£0.053 (vs UK£0.13 in 1H 2020)The company reported a soft first half result with weaker earnings and profit margins, although revenues improved. First half 2021 results: Revenue: UK£147.5m (up 6.7% from 1H 2020). Net income: UK£11.7m (down 55% from 1H 2020). Profit margin: 7.9% (down from 19% in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Mar 09Revenue beats expectationsRevenue exceeded analyst estimates by 1.3%. Over the next year, revenue is forecast to grow 18%, compared to a 57% growth forecast for the Biotechs industry in Germany.
Is New 90 Day High Low • Feb 13New 90-day high: €19.25The company is up 25% from its price of €15.36 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.75 per share.
お知らせ • Feb 10Abingdon Health Signs Collaboration and Co-Marketing Agreement with AbcamAbingdon Health Plc has signed a collaboration and co-marketing agreement with Abcam plc. The Parties intend to establish a collaborative strategic relationship to enable them to identify and maximise opportunities for the provision of each Party’s respective products and services, including the wider Abcam reagent portfolio and Abingdon Health’s rapid test contract development and manufacturing services. Under the terms of the agreement, Abcam will be the preferred supplier to Abingdon of gold nanoparticles and custom conjugation reagents and services, for the Company’s lateral flow assays. Custom conjugation reagents will include a combination of an affinity binding reagent such as an antibody, and signal reagents such as the colloidal gold which provides the colour output in a lateral flow assay. Securing a reliable source for custom conjugation reagents ensures reliable supply chains of critical reagents for customers of Abingdon by providing access to the reagents, colloidal gold and specialist conjugation services of Abcam.
お知らせ • Jan 29Abcam plc Appoints Non-Executive DirectorsAbcam plc announced the appointments of Bessie Lee and Mark Capone as non-executive Directors with immediate effect. Based in China, Bessie Lee is the Chief Executive Officer of Withinlink. Based in the US, Mark Capone is an accomplished life sciences executive with more than 35 years’ experience. He spent over 17 years with Myriad Genetics, latterly as Chief Executive Officer and President, over which time he grew the company into a leading global precision medicine company.
Is New 90 Day High Low • Jan 13New 90-day high: €17.98The company is up 29% from its price of €13.91 on 15 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.22 per share.
お知らせ • Dec 23Abcam plc to Report Q2, 2021 Results on Mar 08, 2021Abcam plc announced that they will report Q2, 2021 results on Mar 08, 2021
お知らせ • Nov 04Abcam plc, Annual General Meeting, Dec 04, 2020Abcam plc, Annual General Meeting, Dec 04, 2020, at 12:00 Coordinated Universal Time. Location: Discovery Drive, Cambridge Biomedical Campus Cambridge United Kingdom Agenda: To consider and adopt the reports of the directors and the financial statements for the year ended 30 June 2020, together with the independent auditor’s report; to consider and approve the Annual report on directors’ remuneration for the year ended 30 June 2020, as set out on pages 84 to 93 of the annual report and accounts.; to consider re-appoint PricewaterhouseCoopers LLP as auditor of the company to hold office until the conclusion of the next general meeting at which accounts are laid before the company; to consider and authorise the Audit and Risk Committee to fix the remuneration of the auditor; and to consider election of director.
Is New 90 Day High Low • Oct 22New 90-day high: €15.13The company is up 5.0% from its price of €14.42 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.69 per share.
Reported Earnings • Oct 04Full year earnings released - EPS €0.06Over the last 12 months the company has reported total profits of UK£12.5m, down 72% from the prior year. Total revenue was UK£260.0m over the last 12 months, largely unchanged from the prior year. Profit margins were 4.8%, which is lower than the 17% margin from last year. The decrease in margin was driven by higher expenses.
Recent Insider Transactions • Sep 25Non-Executive Chairman recently bought €49k worth of stockOn the 17th of September, Peter Allen bought around 4k shares on-market at roughly €13.73 per share. This was the largest purchase by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months.
お知らせ • Jul 20Abcam plc to Report Fiscal Year 2020 Results on Sep 14, 2020Abcam plc announced that they will report fiscal year 2020 results on Sep 14, 2020